Technical Analysis for ONCO - Onconetix, Inc.

Grade Last Price % Change Price Change
F 0.11 0.36% 0.00
ONCO closed up 0.36 percent on Wednesday, May 15, 2024, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Earnings due: May 30
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
NR7 Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Spinning Top Other 0.36%
Inside Day Range Contraction 0.36%
Gapped Down Weakness 0.36%
Lower Bollinger Band Touch Weakness 0.36%
Inside Day Range Contraction -1.59%
Lower Bollinger Band Touch Weakness -1.59%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 20 hours ago
20 DMA Resistance about 20 hours ago
10 DMA Resistance about 20 hours ago
Up 5% about 20 hours ago
Up 3% about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Onconetix, Inc. (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia

Is ONCO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.58
52 Week Low 0.1001
Average Volume 326,157
200-Day Moving Average 0.35
50-Day Moving Average 0.14
20-Day Moving Average 0.12
10-Day Moving Average 0.11
Average True Range 0.01
RSI (14) 38.27
ADX 12.28
+DI 18.46
-DI 19.56
Chandelier Exit (Long, 3 ATRs) 0.10
Chandelier Exit (Short, 3 ATRs) 0.14
Upper Bollinger Bands 0.13
Lower Bollinger Band 0.11
Percent B (%b) 0.26
BandWidth 20.78
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram 0.001
Fundamentals Value
Market Cap 2.49 Million
Num Shares 22.3 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.36
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.12
Resistance 3 (R3) 0.12 0.12 0.12
Resistance 2 (R2) 0.12 0.12 0.12 0.12
Resistance 1 (R1) 0.12 0.12 0.12 0.12 0.12
Pivot Point 0.11 0.11 0.11 0.11 0.11
Support 1 (S1) 0.11 0.11 0.11 0.11 0.10
Support 2 (S2) 0.11 0.11 0.11 0.10
Support 3 (S3) 0.10 0.11 0.10
Support 4 (S4) 0.10